Interpretation of updated NCCN guidelines for small cell lung cancer (version 1. 2022)_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

JIAN Zheng ^简 , ZHANG Yajie ^简 , ZHANG Jiahao ,  LI Hecheng

Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, P.R.China;

Corresponding author：

LI Hecheng, Email: lihecheng2000@hotmail.com

Keywords：

Small cell lung cancer; NCCN guidelines; update of version 1, 2022; interpretation of guideline

DOI：

10.7507/1007-4848.202109043

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The National Comprehensive Cancer Network (NCCN) released the latest version 1, 2022 of "NCCN guidelines for the clinical diagnosis and treatment of small cell lung cancer" (hereinafter referred to as "guideline"). Based on high-quality evidence-based medicine, this guideline provides references of clinical diagnosis and treatment for clinicians around the world. Compared with the version 3, 2021 of the "guideline", updates and revisions mainly focused on the progress of radiotherapy and systemic treatment. This article will interpret the updated therapy content in this new version of the "guideline".

Citation： JIAN Zheng, ZHANG Yajie, ZHANG Jiahao, LI Hecheng. Interpretation of updated NCCN guidelines for small cell lung cancer (version 1. 2022). Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2021, 28(11): 1272-1276. doi: 10.7507/1007-4848.202109043 Copy

1.	Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin, 2021, 71(1): 7-33.
2.	Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer. Nat Rev Dis Primers, 2021, 7(1): 3.
3.	Lutschg JH. Lung cancer. N Engl J Med, 2009, 360(1): 87-88.
4.	Travis WD, Brambilla E, Burke AP, et al. Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol, 2015, 10(9): 1240-1242.
5.	Kalemkerian GP, Loo BW, Akerley W, et al. NCCN guidelines insights: Small cell lung cancer, Version 2.2018. J Natl Compr Canc Netw, 2018, 16(10): 1171-1182.
6.	Herzog BH, Devarakonda S, Govindan R. Overcoming chemotherapy resistance in SCLC. J Thorac Oncol, 2021: S1556-0864(21)02333-9.
7.	TECENTRIQ (atezolizumab) [package insert]. Genentech, Inc, South San Francisco, 2019.
8.	TECENTRIQ (atezolizumab) [summary of product characteristics]. Roche Registration Limited, Welwyn Garden City, 2019.
9.	Spigel DR, Vicente D, Ciuleanu TE, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Ann Oncol, 2021, 32(5): 631-641.
10.	Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic small-cell lung cancer: Results from the KEYNOTE-028 and KEYNOTE-158 Studies. J Thorac Oncol, 2020, 15(4): 618-627.
11.	von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol, 1999, 17(2): 658-667.
12.	Grønberg BH, Halvorsen TO, Fløtten Ø, et al. Randomized phase Ⅱtrial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer. Acta Oncol, 2016, 55(5): 591-597.
13.	Grønberg BH, Killingberg KT, Fløtten Ø, et al. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: An open-label, randomised, phase 2 trial. Lancet Oncol, 2021, 22(3): 321-331.
14.	Qiu B, Li Q, Liu J, et al. Moderately hypofractionated once-daily compared with twice-daily thoracic radiation therapy concurrently with etoposide and cisplatin in limited-stage small cell lung cancer: A multicenter, phase Ⅱ, randomized trial. Int J Radiat Oncol Biol Phys, 2021, 111(2): 424-435.
15.	Brown PD, Gondi V, Pugh S, et al. Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: Phase Ⅲ trial NRG oncology CC001. J Clin Oncol, 2020, 38(10): 1019-1029.
16.	Belderbos JSA, De Ruysscher DKM, De Jaeger K, et al. Phase Ⅲ randomized trial of prophylactic cranial irradiation with or without hippocampus avoidance in SCLC (NCT01780675). J Thorac Oncol, 2021, 16(5): 840-849.
17.	Rodríguez de Dios N, Couñago F, Murcia-Mejía M, et al. Randomized phase Ⅲ trial of prophylactic cranial irradiation with or without hippocampal avoidance for small-cell lung cancer (PREMER): A GICOR-GOECP-SEOR Study. J Clin Oncol, 2021: JCO2100639.
18.	Gong L, Wang QI, Zhao L, et al. Factors affecting the risk of brain metastasis in small cell lung cancer with surgery: Is prophylactic cranial irradiation necessary for stage Ⅰ-Ⅲ disease? Int J Radiat Oncol Biol Phys, 2013, 85(1): 196-200.
19.	Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med, 2007, 357(7): 664-672.
20.	Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol, 2017, 18(5): 663-671.

1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin, 2021, 71(1): 7-33.
2. Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer. Nat Rev Dis Primers, 2021, 7(1): 3.
3. Lutschg JH. Lung cancer. N Engl J Med, 2009, 360(1): 87-88.
4. Travis WD, Brambilla E, Burke AP, et al. Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol, 2015, 10(9): 1240-1242.
5. Kalemkerian GP, Loo BW, Akerley W, et al. NCCN guidelines insights: Small cell lung cancer, Version 2.2018. J Natl Compr Canc Netw, 2018, 16(10): 1171-1182.
6. Herzog BH, Devarakonda S, Govindan R. Overcoming chemotherapy resistance in SCLC. J Thorac Oncol, 2021: S1556-0864(21)02333-9.
7. TECENTRIQ (atezolizumab) [package insert]. Genentech, Inc, South San Francisco, 2019.
8. TECENTRIQ (atezolizumab) [summary of product characteristics]. Roche Registration Limited, Welwyn Garden City, 2019.
9. Spigel DR, Vicente D, Ciuleanu TE, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Ann Oncol, 2021, 32(5): 631-641.
10. Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic small-cell lung cancer: Results from the KEYNOTE-028 and KEYNOTE-158 Studies. J Thorac Oncol, 2020, 15(4): 618-627.
11. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol, 1999, 17(2): 658-667.
12. Grønberg BH, Halvorsen TO, Fløtten Ø, et al. Randomized phase Ⅱtrial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer. Acta Oncol, 2016, 55(5): 591-597.
13. Grønberg BH, Killingberg KT, Fløtten Ø, et al. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: An open-label, randomised, phase 2 trial. Lancet Oncol, 2021, 22(3): 321-331.
14. Qiu B, Li Q, Liu J, et al. Moderately hypofractionated once-daily compared with twice-daily thoracic radiation therapy concurrently with etoposide and cisplatin in limited-stage small cell lung cancer: A multicenter, phase Ⅱ, randomized trial. Int J Radiat Oncol Biol Phys, 2021, 111(2): 424-435.
15. Brown PD, Gondi V, Pugh S, et al. Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: Phase Ⅲ trial NRG oncology CC001. J Clin Oncol, 2020, 38(10): 1019-1029.
16. Belderbos JSA, De Ruysscher DKM, De Jaeger K, et al. Phase Ⅲ randomized trial of prophylactic cranial irradiation with or without hippocampus avoidance in SCLC (NCT01780675). J Thorac Oncol, 2021, 16(5): 840-849.
17. Rodríguez de Dios N, Couñago F, Murcia-Mejía M, et al. Randomized phase Ⅲ trial of prophylactic cranial irradiation with or without hippocampal avoidance for small-cell lung cancer (PREMER): A GICOR-GOECP-SEOR Study. J Clin Oncol, 2021: JCO2100639.
18. Gong L, Wang QI, Zhao L, et al. Factors affecting the risk of brain metastasis in small cell lung cancer with surgery: Is prophylactic cranial irradiation necessary for stage Ⅰ-Ⅲ disease? Int J Radiat Oncol Biol Phys, 2013, 85(1): 196-200.
19. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med, 2007, 357(7): 664-672.
20. Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol, 2017, 18(5): 663-671.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Interpretation of updated NCCN guidelines for small cell lung cancer (version 1. 2022)

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content